Latest Research Development News

Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.

1414 Degrees Ltd advances its transformation into a full-service decarbonised energy provider, delivering key technology and commercial milestones in Q3 FY25 while maintaining a stable cash position.

Empire Energy Group reported significant cash outflows in Q1 2025 driven by exploration and infrastructure investments but bolstered its liquidity with new financing facilities, including a Midstream Infrastructure Facility for the Carpentaria Gas Plant.

CurveBeam AI Limited reported a $4.367 million net operating cash outflow for Q3 2025 but anticipates a significant improvement in cash flow driven by device installations and customer receipts, with no immediate plans for capital raising.

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Titomic Limited has entered a strategic teaming agreement with REPKON USA to jointly develop and apply its kinetic fusion cold spray technology for advanced defense manufacturing, focusing on repairs and performance enhancements of critical military assets.

Li-S Energy reports a $2.67 million net loss for H1 FY25 but marks significant milestones in lithium sulfur battery production and strategic partnerships.

Argenica Therapeutics reported a 16% reduction in half-year losses to $1.19 million, buoyed by a 29% increase in other income largely from R&D tax incentives, as it advances its neuroprotective drug development.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.